Chlamydia trachomatis
Chlamydia trachomatis in brown
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Chlamydiota
Class: Chlamydiia
Order: Chlamydiales
Family: Chlamydiaceae
Genus: Chlamydia
Species:
C. trachomatis
Binomial name
Chlamydia trachomatis
(Busacca 1935) Rake 1957 emend. Everett et al. 1999[1]
Synonyms
  • Rickettsia trachomae [sic] Busacca 1935
  • Rickettsia trachomatis (Busacca 1935) Foley and Parrot 1937
  • Chlamydozoon trachomatis (Busacca 1935) Moshkovski 1945

Chlamydia trachomatis (/kləˈmɪdiə trəˈkoʊmətɪs/), commonly known as chlamydia,[2] is a bacterium that causes chlamydia, which can manifest in various ways, including: trachoma, lymphogranuloma venereum, nongonococcal urethritis, cervicitis, salpingitis, pelvic inflammatory disease. C. trachomatis is the most common infectious cause of blindness and the most common sexually transmitted bacterium.[3]

Different types of C. trachomatis cause different diseases. The most common strains cause disease in the genital tract, while other strains cause disease in the eye or lymph nodes. Like other Chlamydia species, the C. trachomatis life cycle consists of two morphologically distinct life stages: elementary bodies and reticulate bodies. Elementary bodies are spore-like and infectious, whereas reticulate bodies are in the replicative stage and are seen only within host cells.

Description

Chlamydia trachomatis is a gram-negative bacterium that can replicate only within a host cell.[3] Over the course of the C. trachomatis life cycle, the bacteria take on two distinct forms. Elementary bodies are 200 to 400 nanometers across, and are surrounded by a rigid cell wall that allows them to survive outside of a host cell.[3][4] This form can initiate a new infection if it comes into contact with a susceptible host cell.[3] Reticulate bodies are 600 to 1500 nanometers across, and are found only within host cells.[4] Neither form is motile.[4]

The C. trachomatis genome is substantially smaller than that of many other bacteria at approximately 1.04 megabases, encoding approximately 900 genes.[3] Several important metabolic functions are not encoded in the C. trachomatis genome, and instead, are likely scavenged from the host cell.[3] In addition to the chromosome that contains most of the genome, nearly all C. trachomatis strains carry a 7.5 kilobase plasmid that contains 8 genes.[4] The role of this plasmid is unknown, though strains without the plasmid have been isolated, suggesting it is not required for survival of the bacterium.[4]

Life cycle

Life cycle

Like other Chlamydia species, C. trachomatis has a life cycle consisting of two morphologically distinct forms. First, C. trachomatis attaches to a new host cell as a small spore-like form called the elementary body.[5] The elementary body enters the host cell, surrounded by a host vacuole, called an inclusion.[5] Within the inclusion, C. trachomatis transforms into a larger, more metabolically active form called the reticulate body.[5] The reticulate body substantially modifies the inclusion, making it a more hospitable environment for rapid replication of the bacteria, which occurs over the following 30 to 72 hours.[5] The massive number of intracellular bacteria then transition back to resistant elementary bodies, before causing the cell to rupture and being released into the environment.[5] These new elementary bodies are then shed in the semen or released from epithelial cells of the female genital tract, and attach to new host cells.[6]

Classification

C. trachomatis are bacteria in the genus Chlamydia, a group of obligate intracellular parasites of eukaryotic cells.[3] Chlamydial cells cannot carry out energy metabolism and they lack biosynthetic pathways.[7]

C. trachomatis strains are generally divided into three biovars based on the type of disease they cause. These are further subdivided into several serovars based on the surface antigens recognized by the immune system.[3] Serovars A through C cause trachoma, which is the world's leading cause of preventable infectious blindness.[8] Serovars D through K infect the genital tract, causing pelvic inflammatory disease, ectopic pregnancies, and infertility. Serovars L1 through L3 cause an invasive infection of the lymph nodes near the genitals, called lymphogranuloma venereum.[3]

C. trachomatis is thought to have diverged from other Chlamydia species around 6 million years ago. This genus contains a total of nine species: C. trachomatis, C. muridarum, C. pneumoniae, C. pecorum, C. suis, C. abortus, C. felis, C. caviae, and C. psittaci. The closest relative to C. trachomatis is C. muridarum, which infects mice.[5] C. trachomatis along with C. pneumoniae have been found to infect humans to a greater extent. C. trachomatis exclusively infects humans. C. pneumoniae is found to also infect horses, marsupials, and frogs. Some of the other species can have a considerable impact on human health due to their known zoonotic transmission.[citation needed]

Strains that cause lymphogranuloma venereum (Serovars L1 to L3)

Most prevalent genital strains (Serovars D-F)

Less prevalent genital strains (Serovars G-K, and some strains of Serovar D)

Ocular strains (Serovars A-C)

Role in disease

See also: Chlamydia infection

Clinical signs and symptoms of C. trachomatis infection in the genitalia present as the chlamydia infection, which may be asymptomatic or may resemble a gonorrhea infection.[9] Both are common causes of multiple other conditions including pelvic inflammatory disease and urethritis.[10]

C. trachomatis is the single most important infectious agent associated with blindness (trachoma), and it also affects the eyes in the form of inclusion conjunctivitis and is responsible for about 19% of adult cases of conjunctivitis.[11]

C. trachomatis in the lungs presents as the chlamydia pneumoniae respiratory infection and can affect all ages.[12]

Pathogenesis

Elementary bodies are generally present in the semen of infected men and vaginal secretions of infected women.[6] When they come into contact with a new host cell, the elementary bodies bind to the cell via interaction between adhesins on their surface and several host receptor proteins and heparan sulfate proteoglycans.[3] Once attached, the bacteria inject various effector proteins into the host cell using a type three secretion system.[3] These effectors trigger the host cell to take up the elementary bodies and prevent the cell from triggering apoptosis.[3] Within 6 to 8 hours after infection, the elementary bodies transition to reticulate bodies and a number of new effectors are synthesized.[3] These effectors include a number of proteins that modify the inclusion membrane, called Inc proteins, as well as proteins that redirect host vesicles to the inclusion.[3] 8 to 16 hours after infection, another set of effectors are synthesized, driving acquisition of nutrients from the host cell.[3] At this stage, the reticulate bodies begin to divide, coinciding with the expansion of the inclusion.[3] If several elementary bodies have infected a single cell, their inclusions will fuse at this point to create a single large inclusion in the host cell.[3] From 24 to 72 hours after infection, reticulate bodies transition to elementary bodies which are released either by lysis of the host cell or extrusion of the entire inclusion into the host genital tract.[3]

Presentation

Most people infected with C. trachomatis are asymptomatic. However, the bacteria can present in one of three ways: genitourinary (genitals), pulmonary (lungs), and ocular (eyes).[13]

Genitourinary cases can include genital discharge, vaginal bleeding, itchiness (pruritus), painful urination (dysuria), among other symptoms.[14] Often, symptoms are similar to those of a urinary tract infection.[citation needed]

When C. trachomatis presents in the eye in the form of trachoma it begins by gradually thickening the eyelids, and eventually begins to pull the eyelashes into the eyelid.[15] In the form of inclusion conjunctivitis the infection presents with redness, swelling, mucopurulent discharge from the eye, and most other symptoms associated with adult conjunctivitis.[11]

When C. trachomatis is in the lungs in the form of a respiratory infection it typically has symptoms of a runny or stuffy nose, low-grade fever, hoarseness of voice, as well as other symptoms associated with general pneumonia.[16]

C. trachomatis may latently infect the chorionic villi tissues of pregnant women, thereby impacting pregnancy outcome.[17]

Prevalence

Three times as many women are diagnosed with genitourinary C. trachomatis infections as men. Women aged 15–19 have the highest prevalence, followed by women aged 20–24, although the rate of increase of diagnosis is greater for men than for women. Risk factors for genitourinary infections include unprotected sex with multiple partners, lack of condom use, and low socioeconomic status living in urban areas.[13]

Pulmonary infections can occur in infants born to women with active chlamydia infections, although the rate of infection is less than 10%.[14]

Ocular infections take the form of inclusion conjunctivitis or trachoma, both in adults and children. About 84 million worldwide develop C. trachomatis eye infections and 8 million are blinded as a result of the infection.[18] Trachoma is the primary source of infectious blindness in some parts of rural Africa and Asia[19] and is a neglected tropical disease that has been targeted by the World Health Organization for elimination by 2020. Inclusion conjunctivitis from C. trachomatis is responsible for about 19% of adult cases of conjunctivitis.[11]

Treatment

Treatment depends on the infection site, age of the patient, and whether another infection is present. Having a C. trachomatis and one or more other sexually transmitted infections at the same time is possible. Treatment is often done with both partners simultaneously to prevent reinfection. C. trachomatis may be treated with several antibiotic medications, including azithromycin, erythromycin, ofloxacin,[9] and tetracycline.

Tetracycline is the most preferred antibiotic to treat C.trachomatis and has the highest success rate. Azithromycin and doxycycline have equal efficacy to treat C. trachomatis with 97 and 98 percent success, respectively. Azithromycin is dosed as a 1 gram tablet that is taken by mouth as a single dose, primarily to help with concerns of non-adherence.[20] Treatment with generic doxycycline 100  mg twice a day for 7 days has equal success with expensive delayed-release doxycycline 200 mg once a day for 7 days.[20] Erythromycin is less preferred as it may cause gastrointestinal side effects, which can lead to non-adherence. Levofloxacin and ofloxacin are generally no better than azithromycin or doxycycline and are more expensive.[20]

If treatment is necessary during pregnancy, levofloxacin, ofloxacin, tetracycline, and doxycycline are not prescribed. In the case of a patient who is pregnant, the medications typically prescribed are azithromycin, amoxicillin, and erythromycin. Azithromycin is the recommended medication and is taken as a 1 gram tablet taken by mouth as a single dose.[20] Despite amoxicillin having fewer side effects than the other medications for treating antenatal C. trachomatis infection, there have been concerns that pregnant women who take penicillin-class antibiotics can develop a chronic persistent chlamydia infection.[21] Tetracycline is not used because some children and even adults can not withstand the drug, causing harm to the mother and fetus.[20] Retesting during pregnancy can be performed three weeks after treatment. If the risk of reinfection is high, screening can be repeated throughout pregnancy.[9]

If the infection has progressed, ascending the reproductive tract and pelvic inflammatory disease develops, damage to the fallopian tubes may have already occurred. In most cases, the C. trachomatis infection is then treated on an outpatient basis with azithromycin or doxycycline. Treating the mother of an infant with C. trachomatis of the eye, which can evolve into pneumonia, is recommended.[9] The recommended treatment consists of oral erythromycin base or ethylsuccinate 50 mg/kg/day divided into 4 doses daily for two weeks while monitoring for symptoms of infantile hypertrophic pyloric stenosis (IHPS) in infants less than 6 weeks old.[20]

There have been a few reported cases of C.trachomatis strains that were resistant to multiple antibiotic treatments. However, as of 2018, this is not a major cause of concern as antibiotic resistance is rare in C.trachomatis compared to other infectious bacteria.[22]

Laboratory tests

Chlamydia species are readily identified and distinguished from other Chlamydia species using DNA-based tests. Tests for Chlamydia can be ordered from a doctor, a lab or online.[23]

Most strains of C. trachomatis are recognized by monoclonal antibodies (mAbs) to epitopes in the VS4 region of MOMP.[24] However, these mAbs may also cross-react with two other Chlamydia species, C. suis and C. muridarum.[citation needed]

Research

Due to its significance to human health, C. trachomatis is the subject of research in laboratories around the world. The bacteria are commonly grown in immortalised cell lines such as McCoy cells (see RPMI 1640) and HeLa cells.[4] Infectious particles can be quantified by infecting cell layers and counting the number of inclusions, analogous to a plaque assay.[4] Recent research has found that a pair of disulfide bond proteins, which are necessary for C. trachomatis to be able to infect host cells, is very similar to a homologous pair of proteins found in Escherichia coli (E. coli), though the reaction's speed is slower in C. trachomatis.[citation needed]

Other research has been conducted towards the creation of a vaccine against C. trachomatis, finding that it would be very difficult to create a fully effective or even partially effective vaccine since the host's response to infection involves complex immunological pathways that must first be fully understood to ensure that adverse effects are avoided.[28]

Vaccine

In August 2016 a Phase I, double-blind, parallel, randomized, placebo-controlled clinical trial was undertaken by the Danish Statens Serum Institut at Hammersmith Hospital in London, UK, in healthy women aged 19–45 years. The trial aimed to assess the safety and ability to provoke an immune response of the CTH522 chlamydia vaccine. 35 women not infected with chlamydia were included in the trial. The trial included two adjuvants and a saline control group. The vaccine was found to be safe, and all women who received the vaccine regardless of adjuvant developed an immune response against chlamydia.[29]

The Serum Institute has announced that it will continue to pursue funding to move the vaccine into a Phase II trial.[30]

History

C. trachomatis was first described in 1907 by Stanislaus von Prowazek and Ludwig Halberstädter in scrapings from trachoma cases.[31][5] Thinking they had discovered a "mantled protozoan", they named the organism "Chlamydozoa" from the Greek "Chlamys" meaning mantle.[5] Over the next several decades, "Chlamydozoa" was thought to be a virus as it was small enough to pass through bacterial filters and unable to grow on known laboratory media.[5] However, in 1966 electron microscopy studies showed C. trachomatis to be a bacterium.[5] This is essentially due to the fact that they were found to possess DNA, RNA, and ribosomes like other bacteria. It was originally believed that Chlamydia lacked peptidoglycan because researchers were unable to detect muramic acid in cell extracts.[32] Subsequent studies determined that C. trachomatis synthesizes both muramic acid and peptidoglycan, but relegates it to the microbe's division septum and does not utilize it for construction of a cell wall.[33][34] The bacterium is still classified as gram-negative[35]

C. trachomatis agent was first cultured and isolated in the yolk sacs of eggs by Tang Fei-fan et al. in 1957.[36] This was a significant milestone because it became possible to preserve these agents which could then be used for future genomic and phylogenetic studies. The isolation of C. trachomatis coined the term isolate to describe how C. trachomatis has been isolated from an in vivo setting into a "strain" in cell culture.[37] Only a few "isolates" have been studied in detail, limiting the information that can be found on the evolutionary history of C. trachomatis.[36][38]

Evolution

In the 1990s it was shown that there are several species of Chlamydia. Chlamydia trachomatis was first described in historical records in Ebers papyrus written between 1553 and 1550 BC.[39] In the ancient world, it was known as the blinding disease trachoma. The disease may have been closely linked with humans and likely predated civilization.[40] It is now known that C. trachomatis comprises 19 serovars which are identified by monoclonal antibodies that react to epitopes on the major outer-membrane protein (MOMP).[41] Comparison of amino acid sequences reveals that MOMP contains four variable segments: S1,2 ,3 and 4. Different variants of the gene that encodes for MOMP, differentiate the genotypes of the different serovars. The antigenic relatedness of the serovars reflects the homology levels of DNA between MOMP genes, especially within these segments.[42]

Furthermore, there have been over 220 Chlamydia vaccine trials done on mice and other non-human host species to target C. muridarum and C. trachomatis strains. However, it has been difficult to translate these results to the human species due to physiological and anatomical differences. Future trials are working with closely related species to the human.[43]

See also

References

  1. ^ J.P. Euzéby. "Chlamydia". List of Prokaryotic names with Standing in Nomenclature. Retrieved 2008-09-11.
  2. ^ "Chlamydia trachomatis". Retrieved 2015-11-18.[dead link]
  3. ^ a b c d e f g h i j k l m n o p q r Elwell C, Mirrashidi K, Engel J (2016). "Chlamydia cell biology and pathogenesis". Nature Reviews Microbiology. 14 (6): 385–400. doi:10.1038/nrmicro.2016.30. PMC 4886739. PMID 27108705.
  4. ^ a b c d e f g Kuo CC, Stephens RS, Bavoil PM, Kaltenboeck B (2015). "Chlamydia". In Whitman WB (ed.). Bergey's Manual of Systematics of Archaea and Bacteria. John Wiley & Sons. pp. 1–28. doi:10.1002/9781118960608.gbm00364. ISBN 9781118960608.
  5. ^ a b c d e f g h i j Nunes A, Gomes JP (2014). "Evolution, Phylogeny, and molecular epidemiology of Chlamydia". Infection, Genetics and Evolution. 23: 49–64. doi:10.1016/j.meegid.2014.01.029. PMID 24509351.
  6. ^ a b Witkin SS, Minis E, Athanasiou A, Leizer J, Linhares IM (2017). "Chlamydia trachomatis:the persistent pathogen". Clinical and Vaccine Immunology. 24 (10): e00203–17. doi:10.1128/CVI.00203-17. PMC 5629669. PMID 28835360.
  7. ^ Becker, Y. (1996). Molecular evolution of viruses: Past and present (4th ed.). Dordrecht: Kluwer Academic. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK8091/.
  8. ^ Burton, Matthew J.; Trachoma: an overview, British Medical Bulletin, Volume 84, Issue 1, 1 December 2007, Pages 99–116, https://doi.org/10.1093/bmb/ldm034
  9. ^ a b c d Malhotra M, Sood S, Mukherjee A, Muralidhar S, Bala M (September 2013). "Genital Chlamydia trachomatis: an update". Indian J. Med. Res. 138 (3): 303–16. PMC 3818592. PMID 24135174.
  10. ^ Fredlund H, Falk L, Jurstrand M, Unemo M (2004). "Molecular genetic methods for diagnosis and characterisation of Chlamydia trachomatis and Neisseria gonorrhoeae: impact on epidemiological surveillance and interventions". APMIS. 112 (11–12): 771–84. doi:10.1111/j.1600-0463.2004.apm11211-1205.x. PMID 15638837. S2CID 25249521.
  11. ^ a b c Rapoza, Peter A.; Quinn, Thomas C.; Terry, Arlo C.; Gottsch, John D.; Kiessling, Lou Ann; Taylor, Hugh R. (1990-02-01). "A Systematic Approach to the Diagnosis and Treatment of Chronic Conjunctivitis". American Journal of Ophthalmology. 109 (2): 138–142. doi:10.1016/S0002-9394(14)75977-X. ISSN 0002-9394. PMID 2154106.
  12. ^ Gautam, Jeevan; Krawiec, Conrad (2022), "Chlamydia Pneumonia", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32809709, retrieved 2022-06-26
  13. ^ a b "Chlamydial Infections". The Lecturio Medical Concept Library. Retrieved 8 July 2021.
  14. ^ a b Mishori R, McClaskey EL, WinklerPrins VJ (15 December 2012). "Chlamydia Trachomatis Infections: Screening, Diagnosis, and Management". American Family Physician. 86 (12): 1127–1132. PMID 23316985.
  15. ^ Wolle, Meraf A.; West, Sheila K. (2019-03-04). "Ocular Chlamydia trachomatis infection: elimination with mass drug administration". Expert Review of Anti-infective Therapy. 17 (3): 189–200. doi:10.1080/14787210.2019.1577136. ISSN 1478-7210. PMC 7155971. PMID 30698042.
  16. ^ "Recommendations for the Prevention and Management of Chlamydia trachomatis Infections, 1993". www.cdc.gov. Retrieved 2019-11-05.
  17. ^ Contini C, Rotondo JC, Magagnoli F, Maritati M, Seraceni S, Graziano A, Poggi A, Capucci R, Vesce F, Tognon M, Martini F (2018). "Investigation on silent bacterial infections in specimens from pregnant women affected by spontaneous miscarriage". J Cell Physiol. 234 (1): 100–9107. doi:10.1002/jcp.26952. hdl:11392/2393176. PMID 30078192.
  18. ^ "Trachoma". Prevention of Blindness and Visual Impairment. World Health Organization. Archived from the original on January 28, 2011.
  19. ^ Global Network for Neglected Tropical Diseases. Trachoma interactive fact sheet. http://old.globalnetwork.org/sites/all/modules/globalnetwork/factsheetxml/disease.php?id=9 Accessed February 6, 2011,
  20. ^ a b c d e f "Chlamydial Infections in Adolescents and Adults". Retrieved January 23, 2017.
  21. ^ Welsh, L E; Gaydos, C A; Quinn, T C (1992). "In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae". Antimicrobial Agents and Chemotherapy. 36 (2): 291–294. doi:10.1128/aac.36.2.291. ISSN 0066-4804. PMC 188358. PMID 1318677.
  22. ^ Mestrovic, T (2018). "Molecular Mechanisms of Chlamydia trachomatis resistance to antimicrobial drugs" (PDF). Frontiers in Bioscience. 23 (2): 656–670. doi:10.2741/4611. PMID 28930567. S2CID 11631854.
  23. ^ "Oral Chlamydia Home Testing, Symptoms and Treatment | myLAB Box™". 2019-04-03.
  24. ^ Ortiz L, Angevine M, Kim SK, Watkins D, DeMars R (2000). "T-Cell Epitopes in Variable Segments of Chlamydia trachomatis Major Outer Membrane Protein Elicit Serovar-Specific Immune Responses in Infected Humans". Infect. Immun. 68 (3): 1719–23. doi:10.1128/IAI.68.3.1719-1723.2000. PMC 97337. PMID 10678996.
  25. ^ Price, Malcolm J; Ades, AE; Soldan, Kate; Welton, Nicky J; Macleod, John; Simms, Ian; DeAngelis, Daniela; Turner, Katherine ME; Horner, Paddy J (2016). "The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis". Health Technology Assessment. 20 (22): 1–250. doi:10.3310/hta20220. ISSN 1366-5278. PMC 4819202. PMID 27007215.
  26. ^ Bakshi, Rakesh; Gupta, Kanupriya; Jordan, Stephen J.; Brown, LaDraka' T.; Press, Christen G.; Gorwitz, Rachel J.; Papp, John R.; Morrison, Sandra G.; Lee, Jeannette Y. (2017-04-21). "Immunoglobulin-Based Investigation of Spontaneous Resolution of Chlamydia trachomatis Infection". The Journal of Infectious Diseases. 215 (11): 1653–1656. doi:10.1093/infdis/jix194. ISSN 1537-6613. PMC 5853778. PMID 28444306.
  27. ^ "Chlamydia Tests". Sexual Conditions Health Center. WebMD. Retrieved 2012-08-07.
  28. ^ Vasilevsky, Sam; Greub, Gilbert; Nardelli-Haefliger, Denise; Baud, David (2014-04-01). "Genital Chlamydia trachomatis: Understanding the Roles of Innate and Adaptive Immunity in Vaccine Research". Clinical Microbiology Reviews. 27 (2): 346–370. doi:10.1128/CMR.00105-13. ISSN 0893-8512. PMC 3993100. PMID 24696438.
  29. ^ Abraham, Sonya; Juele, Helene; Bang, Peter; Cheeseman, Hannah; Dohn, Rebecca; Cole, Tom (2019-08-01). "Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial". Lancet Infectious Diseases. 19 (10): P1091-1100. doi:10.1016/S1473-3099(19)30279-8. hdl:10044/1/76146. PMID 31416692. S2CID 201019235.
  30. ^ Follmann, Frank (2020-01-28). "A chlamydia vaccine is on the horizon". Archived from the original on 2021-09-12. Retrieved 2021-05-18.
  31. ^ Christensen, Signe; Halili, Maria A.; Strange, Natalie; Petit, Guillaume A.; Huston, Wilhelmina M.; Martin, Jennifer L.; McMahon, Róisín M. (2019). "Oxidoreductase disulfide bond proteins DsbA and DsbB form an active redox pair in Chlamydia trachomatis, a bacterium with disulfide dependent infection and development". PLOS ONE. 14 (9): e0222595. Bibcode:2019PLoSO..1422595C. doi:10.1371/journal.pone.0222595. ISSN 1932-6203. PMC 6752827. PMID 31536549.
  32. ^ Fox, A., Rogers, J. C., Gilbart, J., Morgan, S., Davis, C. H., Knight, S., & Wyrick, P. B. (1990). Muramic acid is not detectable in Chlamydia psittaci or Chlamydia trachomatis by gas chromatography-mass spectrometry. Infection and immunity, 58(3), 835–7.
  33. ^ Packiam, Mathanraj; Weinrick, Brian; Jacobs, William R.; Maurelli, Anthony T. (2015-09-15). "Structural characterization of muropeptides from Chlamydia trachomatis peptidoglycan by mass spectrometry resolves "chlamydial anomaly"". Proceedings of the National Academy of Sciences. 112 (37): 11660–11665. Bibcode:2015PNAS..11211660P. doi:10.1073/pnas.1514026112. ISSN 0027-8424. PMC 4577195. PMID 26290580.
  34. ^ Liechti, G. W.; Kuru, E.; Hall, E.; Kalinda, A.; Brun, Y. V.; VanNieuwenhze, M.; Maurelli, A. T. (February 2014). "A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia trachomatis". Nature. 506 (7489): 507–510. Bibcode:2014Natur.506..507L. doi:10.1038/nature12892. ISSN 1476-4687. PMC 3997218. PMID 24336210.
  35. ^ "Chlamydial Infections". The Lecturio Medical Concept Library. Retrieved 8 July 2021.
  36. ^ a b Darougar S, Jones BR, Kinnison JR, Vaughan-Jackson JD, Dunlop EM (1972). "Chlamydial infection. Advances in the diagnostic isolation of Chlamydia, including TRIC agent, from the eye, genital tract, and rectum". Br J Vener Dis. 48 (6): 416–20. doi:10.1136/sti.48.6.416. PMC 1048360. PMID 4651177.((cite journal)): CS1 maint: multiple names: authors list (link)
  37. ^ Clarke, Ian (2011). "Evolution of Chlamydia Trachomatis". Annals of the New York Academy of Sciences. 1230 (1): E11–8. Bibcode:2011NYASA1230E..11C. doi:10.1111/j.1749-6632.2011.06194.x. PMID 22239534. S2CID 5388815.
  38. ^ Tang FF, Huang YT, Chang HL, Wong KC (1958). "Further studies on the isolation of the trachoma virus". Acta Virol. 2 (3): 164–70. PMID 13594716.
    Tang FF, Chang HL, Huang YT, Wang KC (June 1957). "Studies on the etiology of trachoma with special reference to isolation of the virus in chick embryo". Chin Med J. 75 (6): 429–47. PMID 13461224.
    Tang FF, Huang YT, Chang HL, Wong KC (1957). "Isolation of trachoma virus in chick embryo". J Hyg Epidemiol Microbiol Immunol. 1 (2): 109–20. PMID 13502539.
  39. ^ Clarke, Ian N. (2011). "Evolution of Chlamydia trachomatis". Annals of the New York Academy of Sciences. 1230 (1): E11–E18. Bibcode:2011NYASA1230E..11C. doi:10.1111/j.1749-6632.2011.06194.x. PMID 22239534. S2CID 5388815.
  40. ^ Weir, E.; Haider, S.; Telio, D. (2004). "Trachoma: Leading cause of infectious blindness". Canadian Medical Association Journal. 170 (8): 1225. doi:10.1503/cmaj.1040286. PMC 385350. PMID 15078842.
  41. ^ Somboonna, Naraporn; Mead, Sally; Liu, Jessica; Dean, Deborah (2008). "Discovering and Differentiating New and Emerging Clonal Populations of Chlamydia trachomatiswith a Novel Shotgun Cell Culture Harvest Assay". Emerging Infectious Diseases. 14 (3): 445–453. doi:10.3201/eid1403.071071. PMC 2570839. PMID 18325260.
  42. ^ Hayes, L. J.; Pickett, M. A.; Conlan, J. W.; Ferris, S.; Everson, J. S.; Ward, M. E.; Clarke, I. N. (1990). "The major outer-membrane proteins of Chlamydia trachomatis serovars a and B: Intra-serovar amino acid changes do not alter specificities of serovar- and C subspecies-reactive antibody-binding domains". Journal of General Microbiology. 136 (8): 1559–1566. doi:10.1099/00221287-136-8-1559. PMID 1702141.
  43. ^ Phillips, Samuel; Quigley, Bonnie L.; Timms, Peter (2019). "Seventy Years of Chlamydia Vaccine Research – Limitations of the Past and Directions for the Future". Frontiers in Microbiology. 10: 70. doi:10.3389/fmicb.2019.00070. ISSN 1664-302X. PMC 6365973. PMID 30766521.

Further reading

External links

More
Scholia has a topic profile for Chlamydia trachomatis.
Sexually transmitted infections (STI)
Bacterial diseases due to gram negative non-proteobacteria (BV4)
Taxon identifiers
Authority control databases: National
Categories